<?xml version='1.0' encoding='utf-8'?>
<document id="15151520"><sentence text="Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients."><entity charOffset="63-72" id="DDI-PubMed.15151520.s1.e0" text="methadone" /></sentence><sentence text="To construct a population pharmacokinetic model for methadone enantiomers in the setting of methadone maintenance treatment for opioid dependence"><entity charOffset="52-61" id="DDI-PubMed.15151520.s2.e0" text="methadone" /><entity charOffset="92-101" id="DDI-PubMed.15151520.s2.e1" text="methadone" /><pair ddi="false" e1="DDI-PubMed.15151520.s2.e0" e2="DDI-PubMed.15151520.s2.e0" /><pair ddi="false" e1="DDI-PubMed.15151520.s2.e0" e2="DDI-PubMed.15151520.s2.e1" /></sentence><sentence text="" /><sentence text="A population pharmacokinetic model was developed using P-Pharm software for rac-, (R)- and (S)-methadone using data (8-13 plasma samples per subject) obtained from 59 methadone maintenance patients during one interdosing interval at steady state"><entity charOffset="167-176" id="DDI-PubMed.15151520.s4.e0" text="methadone" /></sentence><sentence text=" The patients were randomly assigned to either a development (n = 38) or a validation dataset (n = 21)" /><sentence text=" The model was refined by inclusion of all subjects to construct a final basic model, which was used to construct a covariate model" /><sentence text="" /><sentence text="A population-based two-compartment open model with first-order absorption and lag time was developed and validated for all analytes" /><sentence text=" The population geometric mean (coefficient of variation) of maximum a posteriori probability Bayesian estimated values for clearance, terminal half-life and volume of distribution at steady-state of the active (R)-enantiomer were 8" /><sentence text="7 (42%) l h(-1), 51 (45%) h and 597 (45%) l, respectively" /><sentence text=" For all analytes, the volume of the central compartment was decreased with increasing plasma alpha(1)-acid glycoprotein concentration and was lower in females, while the delay in absorption was longer at higher doses" /><sentence text=" No covariates were identified for apparent oral clearance" /><sentence text=" The apparent oral clearance of (R)-methadone (geometric mean ratio; 95% confidence interval) was 105% (99, 110), that of (S)-methadone (P = 0"><entity charOffset="32-45" id="DDI-PubMed.15151520.s13.e0" text="(R)-methadone" /><entity charOffset="122-135" id="DDI-PubMed.15151520.s13.e1" text="(S)-methadone" /><pair ddi="false" e1="DDI-PubMed.15151520.s13.e0" e2="DDI-PubMed.15151520.s13.e0" /><pair ddi="false" e1="DDI-PubMed.15151520.s13.e0" e2="DDI-PubMed.15151520.s13.e1" /></sentence><sentence text="19), while (R)-methadone V(c)/F (154%; 151, 157), V(dss) /F (173%; 164, 183), t(1/2beta) (162%; 153, 172) and mean residence time (166%; 156, 176) were significantly greater (P &lt; 0"><entity charOffset="30-31" id="DDI-PubMed.15151520.s14.e0" text="F" /><entity charOffset="58-59" id="DDI-PubMed.15151520.s14.e1" text="F" /><pair ddi="false" e1="DDI-PubMed.15151520.s14.e0" e2="DDI-PubMed.15151520.s14.e0" /><pair ddi="false" e1="DDI-PubMed.15151520.s14.e0" e2="DDI-PubMed.15151520.s14.e1" /></sentence><sentence text="0001) than for (S)-methadone"><entity charOffset="15-28" id="DDI-PubMed.15151520.s15.e0" text="(S)-methadone" /></sentence><sentence text=" The population pharmacokinetic models were able to predict accurately oral clearance values from limited (one or two samples) blood sampling protocols" /><sentence text="" /><sentence text="The substantial stereoselectivity in methadone disposition reinforces the potential for misinterpretation of racemic methadone disposition data"><entity charOffset="37-46" id="DDI-PubMed.15151520.s18.e0" text="methadone" /><entity charOffset="109-126" id="DDI-PubMed.15151520.s18.e1" text="racemic methadone" /><pair ddi="false" e1="DDI-PubMed.15151520.s18.e0" e2="DDI-PubMed.15151520.s18.e0" /><pair ddi="false" e1="DDI-PubMed.15151520.s18.e0" e2="DDI-PubMed.15151520.s18.e1" /></sentence><sentence text=" The marked interindividual variability in (R)-methadone clearance, with no covariates identified, highlights the need for alternative methods to determine an individual's metabolic clearance"><entity charOffset="43-56" id="DDI-PubMed.15151520.s19.e0" text="(R)-methadone" /></sentence><sentence text=" The ability to predict (R)-methadone clearance from one to two blood samples at steady state may prove clinically useful if a drug-drug interaction or poor adherence are suspected and guide the prescriber in deciding if a client's request for a dose increase is warranted or whether an alternative opioid would be more appropriate"><entity charOffset="24-37" id="DDI-PubMed.15151520.s20.e0" text="(R)-methadone" /><entity charOffset="299-305" id="DDI-PubMed.15151520.s20.e1" text="opioid" /><pair ddi="false" e1="DDI-PubMed.15151520.s20.e0" e2="DDI-PubMed.15151520.s20.e0" /><pair ddi="false" e1="DDI-PubMed.15151520.s20.e0" e2="DDI-PubMed.15151520.s20.e1" /></sentence><sentence text="" /></document>